Singapore: BGI-Shenzhen, through its wholly-owned subsidiary Beta Acquisition Corporation, has extended its all cash tender offer to purchase all outstanding shares of common stock of Complete Genomics.

The Depositary for the Offer has indicated that, as of the close of business on October 22, 2012, approximately 6,731,897 shares of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of complete subject to guaranteed delivery procedures.

BGI's financial advisor is Citi, and its legal counsel is O'Melveny & Myers LLP. Complete's financial adviser is Jefferies & Company, and its legal counsel is Latham & Watkins.